Here, we aim to investigate the mechanisms underlying the enhancing effect of RTX-IgG2 on phagocytosis when combined with other RTX isotypes and further explore its potential when combined with mAbs targeting other lymphoma antigens (CD59 and PD-L1). The gene discussed is CD59; the disease is lymphoma.